Table 1 Comparison of positive neutralizing response and negative anti-SARS-CoV-2 spike protein antibody groups
Responders: ≥ 50 IU/mL at day 56 | Non responders: negative or < 50 IU/mL at day 56 | P value | |
|---|---|---|---|
Number of patients | 20 | 7 | |
Sex n (%) | 0.09 | ||
Female (n = 15) | 9 (60) | 6 (40) | |
Male (n = 12) | 11 (91.7) | 1 (8.3) | |
Age in years, median (range) | 69 (46–93) | 74 (47–86) | 0.65 |
Previous lines of therapy, median (range) | 2 (1–8) | 5 (2–11) | 0.03 |
Previous autologous HSCT, n (%) | 0.65 | ||
Had HSCT (n = 9) | 6 (66.7) | 3 (33.3) | |
Did not have HSCT (n = 18) | 12 (66.7) | 6 (33.3) | |
Therapy status n (%) | 0.03 | ||
On therapy (n = 17) | 10 (59) | 7 (41) | |
Not on therapy (n = 10) | 10 (100) | 0 (0) | |
Residual polyclonal gammaglobulins (g/l), median (range) | 4.9 (2–16.6) | 2.4 (1.2–3.8) | 0.0009 |
Disease status (per IMWG criteria) n (%) | |||
Myeloma in complete response or in very good partial response or partial response (n = 24) | 20 (83.3) | 4 (16.7) | 0.002 |
Myeloma in progressive or stable disease under treatment (n = 3) | 0 | 3 (100) | |
Type of therapy, n (%) | |||
Daratumumab-based therapy (n = 9) | 6 (67) | 3 (33) | 0.65 |
Non-Daratumumab-based therapy (n = 18) | 14 (77.8) | 4 (22.2) |